The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.
Gene Therapy: Advances in Translating Technology
Peter W. Marks, MD, PhD
Director, Center for Biologics Evaluation and Research
FDA, United States
Gene therapy is now a reality in the clinic with additional products working toward regulatory approval. Advances in gene editing are expanding the boundaries of what was previously thought possible for gene therapy on somatic cells. However, challenges remain in translating scientific advances into clinical progress. This session will discuss/review recent advances in the field, discuss the existing regulatory framework, and provide perspectives from several different sponsors developing products.
Learning Objective : Identify recent advances in the field of gene therapy; Discuss the existing regulatory framework.
How Has Adeno-Associated Virus (AAV) Evolved?
Terence Flotte, MD
Dean, Provost and Executive Deputy Chancellor
University of Massachusetts Medical School, United States
Update on the Development of the LentiGlobin Program
David Davidson, MD
Chief Medical Officer
bluebird bio, Inc., United States
Past and Recent Landscape of Genome Editing, Technologies, Advances, and Safety